943320-61-4 (3-炔基咪唑并[1,2-B]哒嗪,3-Ethynylimidazo[1,2-b]pyridazine)

CAS号:
943320-61-4
中文名称:
3-炔基咪唑并[1,2-B]哒嗪
英文名称:
3-Ethynylimidazo[1,2-b]pyridazine
分子式:
C8H5N3
分子量:
143.145400762558

3-炔基咪唑并[1,2-B]哒嗪(943320-61-4)名称与标识符

名称

中文别名:
3-炔基咪唑并[1,2-B]哒嗪;3-炔基咪唑[1,2-b]哒嗪;3-乙炔咪唑并[1,2-b]吡嗪;3-乙炔基咪唑并[1,2-b]哒嗪;
英文别名:
3-ethynyl-Imidazo[1,2-b]pyridazine;1 WEEK;3-Ethynylimidazo[1,2-b]pyridazine;3-Ethynylimidazolo[1,2-b]pyridazine;IMIDAZO[1,2-B]PYRIDAZINE, 3-ETHYNYL-;AK141388;VYOHSFQVMLAURO-UHFFFAOYSA-N;3-ethynylimidazo[1,2-b]pyridazin;Imidazo[1,2-b]pyridazine,3-ethynyl-;FCH1189256;PB19496;AX8281570;Y3232;3-Ethynylimidazo[1,2-b]pyridazine (ACI);AKOS022173227;SY097707;5YDU6N6N3Z;943320-61-4;3-Ethynylimidazolo(1,2-b)pyridazine;CS-M1484;DB-083331;DTXSID70676599;SCHEMBL588691;MFCD17012027;3-Ethynylimidazo(1,2-b)pyridazine;Imidazo(1,2-b)pyridazine, 3-ethynyl-;EN300-246672;AS-34548;DTXCID10627348;UNII-5YDU6N6N3Z;

标识符

MDL:
MFCD17012027
InChIKey:
VYOHSFQVMLAURO-UHFFFAOYSA-N
Inchi:
1S/C8H5N3/c1-2-7-6-9-8-4-3-5-10-11(7)8/h1,3-6H
SMILES:
C#CC1N2C(C=CC=N2)=NC=1

3-炔基咪唑并[1,2-B]哒嗪(943320-61-4)物化性质

实验特性

  • 溶解度 : 微溶 (1.2 g/L) (25 ºC),
  • 密度 : 1.15±0.1 g/cm3 (20 ºC 760 Torr),

计算特性

  • 精确分子量 : 143.048347172g/mol
  • 氢键供体数量 : 0
  • 氢键受体数量 : 2
  • 可旋转化学键数量 : 1
  • 同位素质量 : 143.048347172g/mol
  • 重原子数量 : 11
  • 复杂度 : 193
  • 同位素原子数量 : 0
  • 确定原子立构中心数量 : 0
  • 不确定原子立构中心数量 : 0
  • 确定化学键立构中心数量 : 0
  • 不确定化学键立构中心数量 : 0
  • 共价键单元数量 : 1
  • 疏水参数计算参考值(XlogP) : 0.6
  • 拓扑分子极性表面积 : 30.2

3-炔基咪唑并[1,2-B]哒嗪(943320-61-4)安全信息

3-炔基咪唑并[1,2-B]哒嗪(943320-61-4)合成路线

合成路线:1 步
反应条件:
参考文献:
Preparation of piperazine derivative as Bcr-Abl inhibitor for treatment of cancer
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Bcr-abl diploid inhibitor, preparation method therefor, and uses thereof
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of substituted tetrahydronaphthalene amide compound and its pharmaceutically acceptable salt useful in the treatment of cancer
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Piperzine analogs useful for inhibiting RAF dimers and their preparation
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Quinazoline compound and its application in preparation of antitumor drug
, China, , ,
合成路线:1 步
反应条件:
参考文献:
S-type or R-type tetrahydronaphthalene amide compounds, pharmaceutically acceptable salts thereof, preparation method and application thereof in preparation of antitumor drugs
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of substituted benzamide compounds for treatment of tumor
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of bicyclic alkyne derivatives as inhibitors of MAP kinase interacting kinases for therapy
, United Kingdom, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of indan derivatives as protein kinase inhibitors
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of Ponatinib intermediate 3-ethynylimidazo[1,2-b]pyridazine
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of benzo[b][1,4]oxazepine derivative for the treatment of kinase-related disease
, Korea, , ,
合成路线:1 步
反应条件:
参考文献:
Aryl or heteroaryl derivative, and pharmaceutical composition comprising same as active ingredient for treatment of kinase-related disease
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Preparation of N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide and related compound as kinase inhibitor
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Design, Synthesis, and Biological Evaluation of 3-(1H-1,2,3-Triazol-1-yl)benzamide Derivatives as Potent Pan Bcr-Abl Inhibitors Including the Threonine315→Isoleucine315 Mutant
Li, Yupeng; Shen, Mengjie; Zhang, Zhang; Luo, Jinfeng; Pan, Xiaofen; et al, Journal of Medicinal Chemistry, 2012, 55(22), 10033-10046
合成路线:1 步
反应条件:
参考文献:
Aromatic acetylenyl benzamide compounds as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
, China, , ,
合成路线:1 步
反应条件:
参考文献:
Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases
, World Intellectual Property Organization, , ,
合成路线:1 步
反应条件:
参考文献:
Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease
Kaiser, Thomas M. ; Dentmon, Zackery W. ; Dalloul, Christopher E.; Sharma, Savita K.; Liotta, Dennis C., ACS Medicinal Chemistry Letters, 2020, 11(4), 491-496
合成路线:1 步
反应条件:
参考文献:
Structure Guided Design of Potent and Selective Ponatinib-Based Hybrid Inhibitors for RIPK1
Najjar, Malek; Suebsuwong, Chalada; Ray, Soumya S.; Thapa, Roshan J.; Maki, Jenny L.; et al, Cell Reports, 2015, 10(11), 1850-1860
合成路线:1 步
反应条件:
参考文献:
Synthesis of antineoplastic agent Ponatinib
Xie, Ning; Li, Yan-yang; Zhao, Yan-jin; Li, Shu-xin, Zhongguo Xinyao Zazhi, 2013, 22(22), 2688-2691
合成路线:1 步
反应条件:
参考文献:
Design and synthesis of BCR-ABL inhibitors with improved cardiac safety for the treatment of cancer, particularly chronic myeloid leukemias, and neurodegenerative disorders
, World Intellectual Property Organization, , ,